Biotechnology Sector Dominates Pharmaceutical Industry

Strategic Insights -

The biotechnology sector has become increasingly important for the pharmaceutical industry in recent years, with traditional pharmaceutical groups turning to biotech firms to help bolster their early-stage development programs. According to a study by Ernst & Young, the biotechnology sector owns about half the drugs in clinical development. As a result, biotech firms are now in a favorable position, with pharmaceutical companies recognizing the value of getting the groundwork done quickly and efficiently. This is reflected in the fact that the US Food and Drug Administration received more submissions for biologics than for traditional pharmaceutical medicines in 2003.

MorphoSys AG, a German biotech firm, has been at the forefront of this trend, with its unique HuCAL technology allowing it to develop fully-human antibodies quickly and efficiently. The company has already entered into partnerships with major pharmaceutical companies such as Schering AG, Bayer, Roche, and Novartis, and has forecast sales growth of 22% for 2004. MorphoSys's business strategy and impressive technology portfolio have led to a major strategic alliance with Novartis, which now holds a 9.1% stake in the company. The company's proprietary therapeutic antibody development program is also showing promising results, with its MOR 101 compound aimed at treating skin burns and MOR 102 targeting psoriasis.

Aptanomics, another biotech firm, is developing small-molecule drugs based on its proprietary peptide aptamer technology. Peptide aptamers are designed to be specific antagonists of key protein-protein interactions, providing unique opportunities for target validation. The company is currently in talks with several parties regarding potential partnerships and hopes to bring its first in-licensed drug into clinical evaluation by end-2005 or early-2006.

Astex, a UK-based small-molecule discovery firm, is also pioneering fragment-based drug discovery through the use of high-throughput X-ray crystallography. The company's unique Pyramid approach identifies novel small-molecule therapeutics and accelerates drug discovery, enabling the firm to research drug targets previously deemed difficult to manage. Astex has raised £51.4 million ($92.4 million) since its inception and is focused on oncology, with plans to consider going public once two or three of its own candidates reach Phase II.

Key Takeaways:

  • The biotechnology sector has become increasingly important for the pharmaceutical industry, with traditional pharmaceutical groups turning to biotech firms to help bolster their early-stage development programs.
  • Biotech firms such as MorphoSys AG, Aptanomics, and Astex are at the forefront of this trend, with unique technologies and business models allowing them to develop innovative drugs quickly and efficiently.
  • MorphoSys's HuCAL technology has led to partnerships with major pharmaceutical companies and a 22% forecast sales growth for 2004.
  • Aptanomics' peptide aptamer technology provides unique opportunities for target validation and the company is currently in talks with several parties regarding potential partnerships.
  • Astex's Pyramid approach identifies novel small-molecule therapeutics and accelerates drug discovery, enabling the firm to research drug targets previously deemed difficult to manage.
  • The pharmaceutical industry spent $30.5 billion on R&D in 2001, marking a 16% hike over spending in 2000, yet the number of drug candidates entering development has not risen as it should.

Statistics:

  • The biotechnology sector owns about half the drugs in clinical development (Ernst & Young study).
  • MorphoSys AG has forecast sales growth of 22% for 2004.
  • The company's proprietary therapeutic antibody development program is showing promising results, with MOR 101 compound aimed at treating skin burns and MOR 102 targeting psoriasis.
  • Aptanomics is currently in talks with several parties regarding potential partnerships.
  • Astex has raised £51.4 million ($92.4 million) since its inception.
  • The pharmaceutical industry spent $30.5 billion on R&D in 2001.

Sources:

  • Ernst & Young (Marketletter January 19)
  • MorphoSys AG (Marketletter interview with Claudia Gutjahr-Loeser)
  • Aptanomics (Marketletter interview with Michael Courtney)
  • Astex (Marketletter interview with Tim Haines)
  • Pharmaceutical Industry (Marketletter)